drug · antibody
obinutuzumab
Marketedupdated 6mo agoby F. Hoffmann-La Roche Ltd🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2Antibody drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 20 investigational indications.
indications
investigational
Lupus
targets
B-lymphocyte antigen CD20
all catalysts(14)
approval · 14
Nov 1, 2013
approval
GAZYVA (OBINUTUZUMAB) — FDA approval
obinutuzumab
→
Jun 27, 2014
approval
GAZYVA (OBINUTUZUMAB) — FDA approval
obinutuzumab
→
Dec 24, 2014
approval
GAZYVA (OBINUTUZUMAB) — FDA approval
obinutuzumab
→
Sep 23, 2015
approval
GAZYVA (OBINUTUZUMAB) — FDA approval
obinutuzumab
→
Feb 26, 2016
approval
GAZYVA (OBINUTUZUMAB) — FDA approval
obinutuzumab
→
Nov 16, 2017
approval
GAZYVA (OBINUTUZUMAB) — FDA approval
obinutuzumab
→
Nov 16, 2017
approval
GAZYVA (OBINUTUZUMAB) — FDA approval
obinutuzumab
→
Mar 27, 2020
approval
GAZYVA (OBINUTUZUMAB) — FDA approval
obinutuzumab
→
Feb 14, 2022
approval
GAZYVA (OBINUTUZUMAB) — FDA approval
obinutuzumab
→
Jul 12, 2022
approval
GAZYVA (OBINUTUZUMAB) — FDA approval
obinutuzumab
→
Jul 27, 2022
approval
GAZYVA (OBINUTUZUMAB) — FDA approval
obinutuzumab
→
Oct 17, 2025
approval
GAZYVA (OBINUTUZUMAB) — FDA approval
obinutuzumab
→
Oct 17, 2025
approval
GAZYVA (OBINUTUZUMAB) — FDA approval
obinutuzumab
→
Dec 17, 2025
approval
GAZYVA (OBINUTUZUMAB) — FDA approval
obinutuzumab
→
Trials studying obinutuzumab
- phase2Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
- phase3A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis
- phase3A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
- phase3Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
- phase2A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
- phase2An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
- phase3A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- phase3A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy
News(4)
- Novo revamps its direct-to-consumer platform; Roche drug Gazyva approved againPlus news about Uniquity Bio, Commit Biologics, Rosemont Pharmaceuticals, Aytu and Aclaris Therapeutics. Novo relaunches NovoCare direct-to-consumer platform: Novo is revamping its DTC business wit…endpoints · 19h ago
- AstraZeneca pulls EU filing for antibody as CHMP backs Gazyvaro in lupusAstraZeneca has withdrawn its European marketing application for a monoclonal antibody in a subset of amyloidosis patients. The candidate had previously failed two late-stage studies in a broader p…endpoints · 4d ago
- Unlocking cell surface protein research with site-specific labelingApplications in flow cytometry, cell sorting, target validation, and therapeutic discoverybiospace · 2mo ago
- Beeline flies into phase 3 as oral lupus drug soars past placeboA phase 2 trial of Beeline Medicines’ afimetoran has hit its primary endpoint, positioning the biotech to swarm into pivotal development in two forms of lupus.fiercebiotech · 2mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that